Publication on model-informed drug development of CAR-T cell therapy

“This therapy has significantly transformed the treatment of aggressive hematological malignancies.” explains Anna Mc Laughlin, “However, despite its success, up to 60% of patients do not respond long-term. Alternative approaches beyond dose titration are required to increase exposure”

01.09.2023

“This therapy has significantly transformed the treatment of aggressive hematological malignancies.” explains Anna Mc Laughlin, “However, despite its success, up to 60% of patients do not respond long-term. Alternative approaches beyond dose titration are required to increase exposure”…